Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Intern Med ; 61(16): 2497-2502, 2022 Aug 15.
Article in English | MEDLINE | ID: mdl-35110486

ABSTRACT

A 49-year-old woman presented with nephrotic-range proteinuria, microhematuria, and moderate renal dysfunction. Diuretic-resistant refractory ascites associated with nephrotic syndrome were observed. Based on the histopathological findings, the patient was diagnosed with proliferative glomerulonephritis with monoclonal immunoglobulin G deposits (PGNMID). Rituximab was administered due to steroid and immunosuppressive drug resistance, and partial remission was achieved after six months. Cell-free and concentrated ascites reinfusion therapy (CART) performed to treat the refractory ascites improved the ascites and anasarca. Rituximab successfully treated the PGNMID, while CART effectively treated the refractory ascites associated with nephrotic syndrome.


Subject(s)
Glomerulonephritis, Membranoproliferative , Glomerulonephritis , Nephrotic Syndrome , Antibodies, Monoclonal/therapeutic use , Ascites/complications , Ascites/drug therapy , Female , Glomerulonephritis/complications , Glomerulonephritis/drug therapy , Glomerulonephritis, Membranoproliferative/drug therapy , Humans , Immunoglobulin G/therapeutic use , Middle Aged , Nephrotic Syndrome/complications , Nephrotic Syndrome/drug therapy , Rituximab/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL